KRAS G12C

Clinical trials for KRAS G12C explained in plain language.

Never miss a new study

Get alerted when new KRAS G12C trials appear

Sign up with your email to follow new studies for KRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 6 Not yet recruiting 1 Not yet finished but already full! 3 Completed 1

New hope for hard-to-treat lung cancer: drug duo targets KRAS mutation

Disease control Not yet recruiting

This study tests two experimental drugs, Glecirasib and Ivonescimab, together as a first treatment for people with a specific type of advanced lung cancer (KRAS G12C mutation, PD-L1 positive). The goal is to see if the combination is safe and can shrink tumors. About 42 adults wi…

Matched conditions: KRAS G12C

Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control

Last updated May 17, 2026 04:15 UTC

KRAS G12C

Get alerted when new KRAS G12C trials appear

New hope for hard-to-treat lung cancer: drug duo targets KRAS mutation